Navigation Links
Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
Date:4/22/2013

SAN DIEGO, April 22, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that Michael Narachi , president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years.

PhRMA represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.

"PhRMA represents an industry dedicated to the noblest of missions:  Improving the health of patients all over the world," said Narachi. "I'm honored to join the board of PhRMA, and I'm looking forward to being a part of an organization whose mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients."

"I am pleased to welcome a respected industry leader, Mike Narachi , to PhRMA's Board of Directors," said PhRMA President and CEO John J. Castellani . "Mike's many years of experience in the biopharmaceutical sector make him an invaluable addition to our Board as we continue to fight for public policies that recognize the true value of innovative medicines for both patients and the American economy."

Narachi has served as Orexigen's President and Chief Executive Officer and a member of Orexigen's board of directors since March 2009.

Before joining Orexigen, Narachi served as Chairman, CEO and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009, and chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Narachi left Amgen Inc., a leading therapeutics company, where he served as an officer and Vice President and, from 1999 through 2003, as General Manager of Amgen's Anemia Business. After joining Amgen in 1984, he held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. 

Mr. Narachi also currently serves as a member of the Board of Directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Contact: McDavid Stilwell , 858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
3. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
4. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
5. Michael Berman Joins InspireMD Board
6. Secretary of Department of Environmental Protection, Michael Krancer, to Facilitate Networking Session at Pittcon 2013
7. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
8. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
9. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
10. Sigma-Aldrich Elects Michael Marberry As Director
11. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, a breakthrough ... drug360 brings tellic’s expertise in biomedical language processing and machine learning to ... relationships between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... announce its Silver sponsorship and cold chain validation workshop at the Biomanufacturing World ... in San Diego, California. , The Biomanufacturing World Summit brings together ...
(Date:10/22/2019)... ... October 22, 2019 , ... Catalent, a global leader ... and Drug Product Technologies Integration, will participate in a panel session titled “Cell and ... be held at the Gwen Hotel, Chicago, on Oct. 28-30, 2019. , The panel ...
(Date:10/17/2019)... ... October 16, 2019 , ... My Gene Counsel ... has published a new white paper that explores how frequently medical management guidelines ... how patients and medical providers can be kept informed as changes are made. ...
Breaking Biology Technology:
(Date:11/2/2019)... ... , ... Stay on top of current hot topics through free webinars presented ... is free, so be sure to register today to save your place! Participate in ... see our upcoming webinars: , CLINICAL OPERATIONS , November 14 – Leveraging Technology and ...
(Date:10/30/2019)... ... 30, 2019 , ... The 2019 Precision Agriculture Technology Workshop ... will learn about precision agriculture tools used to enhance beef and dairy management ... will have the opportunity to visit Virginia Tech’s agricultural research center, Kentland Farm. ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., ... capital firms, including Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. ... Amberdata to further accelerate its position as the leading data provider of institutional-grade ...
Breaking Biology News(10 mins):